Colposcopy — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Colposcopy is a detailed examination of the cervix, vagina, and vulva using a binocular magnifying instrument called a colposcope, which illuminates and magnifies the cervical surface by six to forty times, allowing identification of abnormal areas invisible to the naked eye. The procedure is performed by a gynaecologist or a specially trained colposcopist in a clinic or outpatient setting and typically follows an abnormal cervical smear (Pap test), a positive high-risk human papillomavirus (HPV) test result, or an abnormal-appearing cervix on physical examination. The key area examined is the transformation zone — where the squamocolumnar junction of the cervix meets, and where cervical intraepithelial neoplasia (CIN) and early invasive cancer most commonly develop. Chemical reagents applied to the cervix during colposcopy temporarily highlight areas of abnormal cell activity: three to five percent acetic acid makes dysplastic cells appear white (acetowhite reaction), and Lugol's iodine differentiates glycogen-rich normal squamous cells (which stain dark brown) from dysplastic cells (which remain pale yellow — Schiller's test). Directed punch biopsies from acetowhite areas provide histological confirmation of the grade of abnormality before treatment decisions are made.

Colposcopy is indicated in women referred from cervical screening programmes following specific abnormal results or clinical findings. In national programmes following current guidelines, the main referral criteria include: a smear showing high-grade dyskaryosis (moderate or severe CIN changes) at any age; two consecutive smears showing low-grade dyskaryosis or borderline nuclear abnormalities over twelve to twenty-four months; a positive high-risk HPV test (particularly HPV 16 or 18) with any degree of cytological abnormality; or a single borderline smear in women who are immunocompromised. Clinical indications for colposcopy regardless of smear results include: a cervix with an abnormal macroscopic appearance (friable, ulcerated, irregular, or suspicious mass), unexplained persistent post-coital bleeding, post-menopausal bleeding with a normal uterine assessment, and unexplained intermenstrual bleeding. Colposcopy is safe in pregnancy and is performed when a high-grade abnormality is suspected, though treatment is deferred to the postpartum period in most cases. Women taking hormone replacement therapy, oral contraceptives, or who have had previous treatment for CIN may require colposcopy as part of specific surveillance protocols.

The patient lies in the dorsal lithotomy position with feet in padded supports. A speculum is gently inserted into the vagina to expose the cervix. The colposcopist first examines the cervix with normal light and then applies three to five percent acetic acid solution using a cotton swab or spray. After one to two minutes, the cervix is examined under the colposcope at low and high magnification. Acetowhite areas are characterised by their borders (sharp versus indistinct), surface contour (flat versus raised), and vascular patterns (punctation, mosaicism, atypical vessels — features grading as normal, low-grade, or high-grade on the Swede or Reid colposcopic index). Lugol's iodine may then be applied to differentiate normal from abnormal tissue. If punch biopsies are indicated, one to four biopsies of two to four millimetres are taken from the most abnormal areas using Tischler or Baby Tischler biopsy forceps. Bleeding from biopsy sites is controlled with silver nitrate solution or Monsel's paste (ferric subsulphate). An endocervical curettage (ECC) may be performed to sample tissue from within the endocervical canal when the transformation zone is not fully visible (unsatisfactory or inadequate colposcopy). The entire procedure takes fifteen to thirty minutes. The entire procedure, including biopsy, is completed within 15–20 minutes.

Colposcopy with directed biopsy provides histological confirmation of CIN grade with accuracy superior to cytology alone, enabling appropriate patient management that avoids both overtreatment of low-grade lesions and undertreatment of high-grade CIN. Colposcopic accuracy varies by examiner experience: in expert hands, sensitivity for high-grade CIN2+ exceeds eighty-five to ninety percent, with specificity of seventy to eighty percent. The addition of directed biopsy improves diagnostic accuracy compared to visual assessment alone and is mandatory before definitive treatment. For low-grade CIN1, colposcopy confirms histology and enables a surveillance strategy (repeat smear and colposcopy at six to twelve months) given that sixty to eighty percent of CIN1 regresses spontaneously within two years. For high-grade CIN2–3, colposcopic confirmation precedes treatment with large loop excision of the transformation zone (LLETZ), which achieves cure in ninety to ninety-five percent of cases. See-and-treat colposcopy — performing LLETZ at the same visit as biopsy without waiting for histology — is appropriate for patients with clearly high-grade acetowhite appearances, reducing the number of appointments and anxiety for patients. Combined with cervical screening, colposcopy is a cornerstone of cervical cancer prevention programmes.

Colposcopy examination without biopsy carries negligible risk. After directed punch biopsy, minor bleeding — dark brown discharge from silver nitrate — lasting one to three days is normal and expected. Heavy bleeding requiring additional intervention (packing, silver nitrate, or electrocautery) occurs in fewer than one percent of patients. Vaginal and cervical infection after biopsy is rare (below one percent) when standard antiseptic technique is observed, but patients should report significant increase in vaginal discharge, offensive odour, or fever. Pelvic pain persisting beyond twenty-four hours with fever warrants assessment for endometritis. An inadequate or unsatisfactory colposcopy — where the entire transformation zone cannot be visualised due to the squamocolumnar junction receding into the endocervical canal, as commonly occurs in postmenopausal women — may necessitate endocervical curettage, repeat colposcopy after oestrogen treatment, or diagnostic excision (cone biopsy) to fully assess the endocervix. Silver nitrate contact with vaginal walls can occasionally cause chemical vaginitis. Colposcopy itself does not affect fertility or pregnancy, though women planning pregnancy should be informed that LLETZ treatment carries a small increased risk of preterm labour (approximately ten to fifteen percent compared to five percent in untreated women) due to reduced cervical length.

After colposcopy examination without biopsy, patients can return to normal activity immediately. If biopsies have been taken, light spotting or dark brown discharge (from silver nitrate or Monsel's solution) lasting one to three days is normal and expected. Tampons, vaginal intercourse, and swimming are avoided for forty-eight hours after biopsy to allow the biopsy sites to heal and reduce infection risk. Normal sanitary pads should be used. Most women experience only mild cramping, manageable with regular paracetamol or ibuprofen. Biopsy histology results typically take two to four weeks and are communicated by letter or at a follow-up appointment. Depending on results, the patient will be advised on surveillance (repeat smear or colposcopy at six to twelve months for CIN1 or normal findings) or treatment (LLETZ for CIN2–3). LLETZ — where a wire loop removes the abnormal transformation zone under local anaesthesia — is performed as a separate appointment or at the same colposcopy visit (see-and-treat). Following LLETZ, patients are advised to avoid intercourse, tampons, and swimming for four weeks to allow complete healing and reduce the risk of haemorrhage and infection.